BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 28314308)

  • 1. Comparison of the Diagnostic Performance of Fibulin-3 and Mesothelin in Patients with Pleural Effusions from Malignant Mesothelioma.
    Battolla E; Canessa PA; Ferro P; Franceschini MC; Fontana V; Dessanti P; Pinelli V; Morabito A; Fedeli F; Pistillo MP; Roncella S
    Anticancer Res; 2017 Mar; 37(3):1387-1391. PubMed ID: 28314308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic value of soluble mesothelin-related peptides in pleural effusion for malignant pleural mesothelioma: An updated meta-analysis.
    Gao R; Wang F; Wang Z; Wu Y; Xu L; Qin Y; Shi H; Tong Z
    Medicine (Baltimore); 2019 Apr; 98(14):e14979. PubMed ID: 30946324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology.
    Canessa PA; Franceschini MC; Ferro P; Battolla E; Dessanti P; Manta C; Sivori M; Pezzi R; Fontana V; Fedeli F; Pistillo MP; Roncella S
    Cancer Invest; 2013 Jan; 31(1):43-50. PubMed ID: 23249166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mesothelin is more useful in pleural effusion than in serum in the diagnosis of pleural mesothelioma.
    Ferro P; Canessa PA; Battolla E; Dessanti P; Franceschini MC; Chiaffi L; Morabito A; Fontana V; Pezzi R; Fedeli F; Pistillo MP; Roncella S
    Anticancer Res; 2013 Jun; 33(6):2707-13. PubMed ID: 23749930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma.
    Creaney J; Dick IM; Meniawy TM; Leong SL; Leon JS; Demelker Y; Segal A; Musk AW; Lee YC; Skates SJ; Nowak AK; Robinson BW
    Thorax; 2014 Oct; 69(10):895-902. PubMed ID: 25037982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis.
    Kirschner MB; Pulford E; Hoda MA; Rozsas A; Griggs K; Cheng YY; Edelman JJ; Kao SC; Hyland R; Dong Y; László V; Klikovits T; Vallely MP; Grusch M; Hegedus B; Dome B; Klepetko W; van Zandwijk N; Klebe S; Reid G
    Br J Cancer; 2015 Sep; 113(6):963-9. PubMed ID: 26263483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
    Pass HI; Wali A; Tang N; Ivanova A; Ivanov S; Harbut M; Carbone M; Allard J
    Ann Thorac Surg; 2008 Jan; 85(1):265-72; discussion 272. PubMed ID: 18154821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic value of mesothelin in pleural fluids: comparison with CYFRA 21-1 and CEA.
    Filiberti R; Parodi S; Libener R; Ivaldi GP; Canessa PA; Ugolini D; Bobbio B; Marroni P
    Med Oncol; 2013 Jun; 30(2):543. PubMed ID: 23532816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mesothelin in serum and pleural effusion in the diagnosis of malignant pleural mesothelioma with non-positive cytology.
    Franceschini MC; Ferro P; Canessa PA; Battolla E; Dessanti P; Valentino A; Casolari L; Fontana V; Pezzi R; Fedeli F; Pistillo MP; Roncella S
    Anticancer Res; 2014 Dec; 34(12):7425-9. PubMed ID: 25503183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of Mesothelin Levels in Pleural Effusion Does Not Help Predict Survival of Patients With Malignant Pleural Mesothelioma.
    Fontana V; Pistillo MP; Vigani A; Canessa PA; Berisso G; Giannoni U; Ferro P; Franceschini MC; Carosio R; Tonarelli M; Rossi C; Dessanti P; Roncella S
    Anticancer Res; 2019 Sep; 39(9):5219-5223. PubMed ID: 31519636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical value of mesothelin in pleural effusions versus histology by medical thoracoscopy: brief report.
    Canessa PA; Ferro P; Manta C; Sivori M; Franceschini MC; Fedeli F; Roncella S
    Med Oncol; 2013; 30(3):649. PubMed ID: 23873013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CCL2, galectin-3, and SMRP combination improves the diagnosis of mesothelioma in pleural effusions.
    Blanquart C; Gueugnon F; Nguyen JM; Roulois D; Cellerin L; Sagan C; Perigaud C; Scherpereel A; Gregoire M
    J Thorac Oncol; 2012 May; 7(5):883-9. PubMed ID: 22729037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pleural effusion biomarkers and computed tomography findings in diagnosing malignant pleural mesothelioma: A retrospective study in a single center.
    Otoshi T; Kataoka Y; Ikegaki S; Saito E; Matsumoto H; Kaku S; Shimada M; Hirabayashi M
    PLoS One; 2017; 12(10):e0185850. PubMed ID: 28968445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarkers for malignant pleural mesothelioma: a meta-analysis.
    Gillezeau CN; van Gerwen M; Ramos J; Liu B; Flores R; Taioli E
    Carcinogenesis; 2019 Nov; 40(11):1320-1331. PubMed ID: 31169881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer.
    Schneider J; Hoffmann H; Dienemann H; Herth FJ; Meister M; Muley T
    J Thorac Oncol; 2008 Nov; 3(11):1317-24. PubMed ID: 18978568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum soluble mesothelin-related protein (SMRP) and fibulin-3 levels correlate with baseline malignant pleural mesothelioma (MPM) tumor volumes but are not useful as biomarkers of response in an immunotherapy trial.
    Katz SI; Roshkovan L; Berger I; Friedberg JS; Alley EW; Simone CB; Haas AR; Cengel KA; Sterman DH; Albelda SM
    Lung Cancer; 2021 Apr; 154():5-12. PubMed ID: 33561782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble Mesothelin-Related Peptides to Monitor Recurrence After Resection of Pleural Mesothelioma.
    Burt BM; Lee HS; Lenge De Rosen V; Hamaji M; Groth SS; Wheeler TM; Sugarbaker DJ
    Ann Thorac Surg; 2017 Nov; 104(5):1679-1687. PubMed ID: 28964420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of TGF-β in pleural effusions for diagnosis and prognostic stratification of malignant pleural mesothelioma.
    Stockhammer P; Ploenes T; Theegarten D; Schuler M; Maier S; Aigner C; Hegedus B
    Lung Cancer; 2020 Jan; 139():124-132. PubMed ID: 31778960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure.
    Demir M; Kaya H; Taylan M; Ekinci A; Yılmaz S; Teke F; Sezgi C; Tanrikulu AC; Meteroglu F; Senyigit A
    Lung; 2016 Jun; 194(3):409-17. PubMed ID: 27032653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma.
    Pass HI; Levin SM; Harbut MR; Melamed J; Chiriboga L; Donington J; Huflejt M; Carbone M; Chia D; Goodglick L; Goodman GE; Thornquist MD; Liu G; de Perrot M; Tsao MS; Goparaju C
    N Engl J Med; 2012 Oct; 367(15):1417-27. PubMed ID: 23050525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.